Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver

ABSTRACT Introduction: Traditional systemic therapies offer limited benefit for advanced cancers of the liver. Immune checkpoints are inhibitory regulators of the immune system and the success of immune checkpoint inhibitors (ICIs) in the treatment of other cancers has led to clinical trials investigating the use of ICIs alone or in combination with other therapies for liver cancers. Area covered: Clinical trials involving ICIs for the treatment of liver cancer were broadly reviewed. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma were examined. Phase I/II trials were prioritized, and relevant phase III trials were discussed. MEDLINE, PubMed, ASCO meeting library, and Web of Science databases were searched with the keywords ‘immune checkpoint inhibitor’ or ‘targeted therapy’ in combination with ‘hepatocellular carcinoma,’ or ‘intrahepatic cholangiocarcinoma’. Major outcomes were safety and efficacy defined by response rate, progression-free survival, or overall survival. Expert opinion: ICIs can improve progression-free and overall survival among patients with advanced disease with an acceptable safety profile. Given the heterogeneity of liver disease, ideal strategies will likely include a combination of ICIs with additional therapies to achieve the most robust and durable response. Additional biomarkers will be needed to guide combination therapy to personalize treatment regimen for patients with primary liver cancers.

[1]  Jianming Xu,et al.  Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial , 2020, Clinical Cancer Research.

[2]  M. Kudo,et al.  Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib , 2020, JAMA oncology.

[3]  S. Jalkanen,et al.  1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer , 2020 .

[4]  M. Kudo,et al.  1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation , 2020, Annals of Oncology.

[5]  Keunchil Park,et al.  Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). , 2020, European journal of cancer.

[6]  A. Nagrial,et al.  Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. , 2020, JAMA oncology.

[7]  M. Kudo,et al.  Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Yulei N. Wang,et al.  Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. , 2020, The Lancet. Oncology.

[9]  Haitao Zhao,et al.  Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. , 2020, Hepatobiliary surgery and nutrition.

[10]  M. Rebelatto,et al.  Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC). , 2020 .

[11]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[12]  Hong Wang,et al.  Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies , 2020, International journal of cancer.

[13]  P. Chow,et al.  IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. , 2020, Future oncology.

[14]  M. Schell,et al.  A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. , 2020, JAMA oncology.

[15]  W. Fang,et al.  Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. , 2020, The Lancet. Oncology.

[16]  N. Azad,et al.  Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). , 2020, Chinese clinical oncology.

[17]  M. Kudo,et al.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Piscaglia,et al.  Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. , 2019, Journal of hepatology.

[19]  Jin-Hyeok Hwang,et al.  High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer , 2019, Scientific Reports.

[20]  A. Vogel,et al.  A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 , 2019, Annals of Oncology.

[21]  T. Blondal,et al.  A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3) , 2019, Annals of Oncology.

[22]  Ching Ngar Wong,et al.  A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL , 2019, Annals of Oncology.

[23]  M. Kudo,et al.  CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) , 2019, Annals of Oncology.

[24]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[25]  A. Mokdad,et al.  Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial , 2019, Targeted Oncology.

[26]  J. Furuse,et al.  Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. , 2019, The lancet. Gastroenterology & hepatology.

[27]  G. Curigliano,et al.  Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies , 2019, Clinical Trials.

[28]  R. Lencioni,et al.  A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Kudo,et al.  Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). , 2019, Journal of Clinical Oncology.

[30]  Z. Meng,et al.  A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer. , 2019, Journal of Clinical Oncology.

[31]  M. Kudo,et al.  Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study. , 2019, Journal of Clinical Oncology.

[32]  A. Maraveyas,et al.  ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) che , 2019, Journal of Clinical Oncology.

[33]  M. Kudo,et al.  First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100). , 2019, Journal of Clinical Oncology.

[34]  S. Steinberg,et al.  Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer , 2019, Hepatology.

[35]  Joon-Oh Park,et al.  AB052. P-20. Phase 2, open-label study of second-line M7824 treatment in patients with locally advanced or metastatic biliary tract cancer , 2019, HepatoBiliary Surgery and Nutrition.

[36]  E. Assenat,et al.  Abstract No. 526 CheckMate-9DX: phase 3, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation , 2019, Journal of Vascular and Interventional Radiology.

[37]  J. Sicklick,et al.  Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study , 2019, Nature Medicine.

[38]  S. Jalkanen,et al.  Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors , 2019, Clinical Cancer Research.

[39]  Y. Doki,et al.  Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). , 2019, Journal of Clinical Oncology.

[40]  Manal M. Hassan,et al.  Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. , 2019, Journal of Clinical Oncology.

[41]  M. Kudo,et al.  Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. , 2019, Journal of Clinical Oncology.

[42]  E. Assenat,et al.  CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  M. Osada,et al.  M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[45]  J. Gulley,et al.  M7824: A promising new strategy to combat cancer immune evasion , 2018, Oncoscience.

[46]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[47]  M. Kudo,et al.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.

[48]  M. Soulen,et al.  A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC). , 2018 .

[49]  R. Herbst,et al.  Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF) , 2018, The oncologist.

[50]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[51]  Rajdeep Chowdhury,et al.  Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight , 2018, Cancer cell international.

[52]  C. Thng,et al.  A phase II open-label, single-centre, non-randomized trial of Y90 transarterial radioembolization in combination with nivolumab in Asian patients with intermediate stage hepatocellular carcinoma: An immunological study of radioembolization in combination with anti-PD1 therapy in HCC. , 2018 .

[53]  C. Atreya,et al.  Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC). , 2018 .

[54]  H. Weir,et al.  Liver cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.

[55]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[56]  Russell Bonneville,et al.  Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[57]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[58]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[59]  Y. Chao,et al.  Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC). , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  S. Ramalingam,et al.  GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817). , 2017 .

[61]  J. Nemunaitis,et al.  Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC). , 2017 .

[62]  M. Rebelatto,et al.  Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. , 2017 .

[63]  S. Steinberg,et al.  Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. , 2017, Journal of hepatology.

[64]  L. Bolondi,et al.  Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. , 2017, The Lancet. Oncology.

[65]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[66]  J. Marrero,et al.  Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. , 2016, Journal of hepatology.

[67]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[68]  L. Bolondi,et al.  Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib , 2016, Therapeutic advances in gastroenterology.

[69]  R. Birge,et al.  Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer , 2016, Cell Death and Differentiation.

[70]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[72]  G. Malaguarnera,et al.  The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies , 2015, BioMed research international.

[73]  T. Pawlik,et al.  Hepatobiliary cancers, version 2.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[74]  T. Pawlik,et al.  Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. , 2014, JAMA surgery.

[75]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[76]  J. Prieto,et al.  A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. , 2013, Journal of hepatology.

[77]  R. Labianca,et al.  Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  L. Roberts,et al.  Immunotherapeutic Approaches to Hepatocellular Carcinoma Treatment , 2012, Liver Cancer.

[79]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[80]  C. Drake,et al.  Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma , 2011, Clinical Cancer Research.

[81]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[82]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[83]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[84]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[85]  L. Lang.  FDA approves sorafenib for patients with inoperable liver cancer. , 2008, Gastroenterology.

[86]  M. Saadeh,et al.  Liver , 2016, Laboratory Investigation.

[87]  J. Taïeb,et al.  Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. , 2013, Journal of hepatology.